WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Forum: Aktien User: Summer.76

https://finance.sina.cn/hkstock/ggyw/2021-12-16/detail-ikyamrmy9275471.d.html?from=wap

Der CRO-Sektor beschleunigte seinen Rückgang am Nachmittag... https://finance.sina.cn/hkstock/ggyw/2021-12-15/detail-ikyakumx4292300.d.html?from=wap

https://www.biospectrumasia.com/news/40/19433/chinas-wuxi-sta-forms-strategic-partnership-with-coherent-biopharma.html

WuXi ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support Global Customers https://www.prnewswire.com/news-releases/wuxi-atu-opens-new-facility-in-philadelphia-tripling-testing-capacity-to-support-global-customers-301423668.html New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry.

WuXi AppTec Reports Strong Third-Quarter 2021 Results https://www.wfmz.com/news/pr_newswire/pr_newswire_health/wuxi-apptec-reports-strong-third-quarter-2021-results/article_85e75845-d42f-50af-92e1-bd9c2ba6c87e.html

Chinese fund managers buy new-energy stocks and ditch tech giants, quarterly portfolio report shows https://www.scmp.com/business/markets/article/3154027/chinese-fund-managers-buy-new-energy-stocks-and-ditch-tech-giants • Sungrow Power Supply, WuXi AppTec and Shanxi Xinghuacun saw the biggest increases in holdings of fund managers in the third quarter • Total assets managed by China’s mutual funds increased 4 per cent quarter on quarter to US$3.7 trillion at the end of September ...

Fitch Upgrades WuXi AppTec's IDR to 'BBB'; Outlook Stable https://www.fitchratings.com/research/corporate-finance/fitch-upgrades-wuxi-apptec-idr-to-bbb-outlook-stable-25-10-2021

Lässt sich auch ohne die App lesen: Pharmaceutical stocks pay attention to growth confirmation  https://specialist.hket.com/article/3086579/%E3%80%90%E8%B4%8F%E9%9D%A2%E8%82%A1%E8%BF%BD%E8%B9%A4%E3%80%91%20%E9%86%AB%E8%97%A5%E8%82%A1%E7%95%99%E6%84%8F%20%20%20%E6%88%90%E9%95%B7%E6%80%A7%E7%A2%BA%E5%AE%9A%20%20%EF%BC%88%E9%99%84%E8%82%A1%E7%A5%A8%E6%8E%A8%E4%BB%8B%EF%BC%89%EF%BC%88%E7%AC%AC%E4%BA%8C%E7%89%88%EF%BC%89 In the medium term, the growth determined by the pharmaceutical sector will still be one of the main directions for investment in the entire market in 2022. October and even Q4 will be the best time to deploy the pharmaceutical sector. This research report will focus on the investment strategy of the pharmaceutical industry and recommend favorite stocks, such as WuXi AppTec (02359) , Cinda Bio (01801) , Ascent Pharmaceuticals (06855) and Rongchang Bio (09995), etc. It is also recommended to pay attention WuXi Biologics (02269) , Tigermed (03347), etc. The main reasons for the obvious signs of stabilization in the pharmaceutical sector: ...

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers https://www.prnewswire.com/news-releases/wuxi-atu-opens-new-manufacturing-facility-to-further-enhance-its-ctdmo-services-for-global-customers-301401893.html WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a leading Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia. As its fourth manufacturing site worldwide, the new facility will supplement WuXi ATU's global footprint and will further join with other sites in the United States, United Kingdom and China to enable global customers with enhanced capacity and efficient services.  ...

WuXi AppTec (02359 HK) 56,000 shares will be listed for circulation on September 16 https://m.jrj.com.cn/madapter/hk/2021/09/10212433417126.shtml Greenway on September 10th | WuXi AppTec (02359 HK) issued an announcement regarding the company's 2018 restricted stock and stock option incentive plan to reserve stock options for the second exercise period. The number of partial exercise shares is 56,448 shares. The time for the listing and circulation of the secondary exercise stock is September 16, 2021.

Aber durchhalten und auch nachkaufen lohnt sich m.M.n. mittel- bis langfristig

Das stimmt.

Hängt ja momentan nicht an den Zahlen, sondern eher daran, was im Land passiert. Geht der WuXi Bio ähnlich. Dort im Forum hatte ich etwa Mitte August Infos eingestellt, warum (nicht nur) die Pharmatitel leiden.

Ok. Das sollte sich doch im Kurs wieder spiegeln

WuXi AppTec Reports Strong 2021 Interim Results https://finance.yahoo.com/news/wuxi-apptec-reports-strong-2021-095200729.html • Revenue Up 45.7% Year-Over-Year to RMB10,537 Million • Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million • Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 • Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-Year to RMB2,448 Million • Adjusted Non-IFRS Diluted EPS Up 58.5% Year-Over-Year to RMB0.84 ...

Major Pharmas Broadly Shorted http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/RUM.210812_111612/hk-stock-news ... WUXI APPTEC (02359 HK) and WUXI BIO (02269 HK) likewise slumped for two consecutive days, with the former dropping to as low as $155.5 at one point; last posted $156.2, down 4.5%. The latter, reaching below its 100MA at one point, lasted stood at $118.8, down 3.8%. ...